These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

82 related items for PubMed ID: 10822902

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Reduced mortality and CD4 cell loss among carriers of the interleukin-10 -1082G allele in a Zimbabwean cohort of HIV-1-infected adults.
    Erikstrup C, Kallestrup P, Zinyama-Gutsire RB, Gomo E, Butterworth AE, Pedersen BK, Ostrowski SR, Gerstoft J, Ullum H.
    AIDS; 2007 Nov 12; 21(17):2283-91. PubMed ID: 18090276
    [Abstract] [Full Text] [Related]

  • 10. Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings.
    Bedell R, Heath KV, Hogg RS, Wood E, Press N, Yip B, O'Shaughnessy MV, Montaner JS.
    Antivir Ther; 2003 Oct 12; 8(5):379-84. PubMed ID: 14640384
    [Abstract] [Full Text] [Related]

  • 11. Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis.
    Sungkanuparph S, Overton ET, Seyfried W, Groger RK, Fraser VJ, Powderly WG.
    Clin Infect Dis; 2005 Nov 01; 41(9):1326-32. PubMed ID: 16206110
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The model for end-stage liver disease score is the best prognostic factor in human immunodeficiency virus 1-infected patients with end-stage liver disease: a prospective cohort study.
    Murillas J, Rimola A, Laguno M, de Lazzari E, Rascón J, Agüero F, Blanco JL, Moitinho E, Moreno A, Miró JM, ESLD-HIV Working Group Investigators.
    Liver Transpl; 2009 Sep 01; 15(9):1133-41. PubMed ID: 19718643
    [Abstract] [Full Text] [Related]

  • 14. CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy.
    Khanna N, Opravil M, Furrer H, Cavassini M, Vernazza P, Bernasconi E, Weber R, Hirschel B, Battegay M, Kaufmann GR, Swiss HIV Cohort Study.
    Clin Infect Dis; 2008 Oct 15; 47(8):1093-101. PubMed ID: 18783328
    [Abstract] [Full Text] [Related]

  • 15. Short communication. Association of the CCR5delta32 mutation with clinical response and >5-year survival following initiation of first triple antiretroviral regimen.
    Brumme ZL, Henrick BM, Brumme CJ, Hogg RS, Montaner JS, Harrigan PR.
    Antivir Ther; 2005 Oct 15; 10(7):849-53. PubMed ID: 16312181
    [Abstract] [Full Text] [Related]

  • 16. Predicting the evolution of Kaposi sarcoma, in the highly active antiretroviral therapy era.
    El Amari EB, Toutous-Trellu L, Gayet-Ageron A, Baumann M, Cathomas G, Steffen I, Erb P, Mueller NJ, Furrer H, Cavassini M, Vernazza P, Hirsch HH, Bernasconi E, Hirschel B, Swiss HIV Cohort Study.
    AIDS; 2008 May 31; 22(9):1019-28. PubMed ID: 18520345
    [Abstract] [Full Text] [Related]

  • 17. [Survival and disease progression in 251 patients with HIV-1 infection. Study of p24 antigen and viral burden as prognosis makers. Their value at 4 years of follow-up].
    Rubio Caballero M, Rubio Rivas C, Nogués Biau A, Falguera Sacrest M, Manonelles Fernández A.
    An Med Interna; 2001 Oct 31; 18(10):517-20. PubMed ID: 11766280
    [Abstract] [Full Text] [Related]

  • 18. Long-term prognosis of HIV-infected patients with Kaposi sarcoma treated with pegylated liposomal doxorubicin.
    Martín-Carbonero L, Palacios R, Valencia E, Saballs P, Sirera G, Santos I, Baldobí F, Alegre M, Goyenechea A, Pedreira J, González del Castillo J, Martínez-Lacasa J, Ocampo A, Alsina M, Santos J, Podzamczer D, González-Lahoz J, Caelyx/Kaposi's Sarcoma Spanish Group.
    Clin Infect Dis; 2008 Aug 01; 47(3):410-7. PubMed ID: 18582203
    [Abstract] [Full Text] [Related]

  • 19. CD4+ guided antiretroviral treatment interruption in HIV infection: a meta-analysis.
    Seminari E, De Silvestri A, Boschi A, Tinelli C.
    AIDS Rev; 2008 Aug 01; 10(4):236-44. PubMed ID: 19092979
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.